Continued interrogation of the NLRP3 inflammasome in heart failure is likely to aid in identifying new targets for therapeutic intervention, which may act synergistically with pharmacologic chaperones to break the cycle of amyloidosis and inflammation. Here, NLRP3 is linked to amyloidosis.